[1]段俊峰 郭美姿.调控性RNA在射血分数保留的心力衰竭中的研究进展[J].心血管病学进展,2026,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.006]
　DUAN Junfeng,GUO Meizi.Regulatory RNA in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2026,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.006]
点击复制

调控性RNA在射血分数保留的心力衰竭中的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2026年1期
页码:
27
栏目:
综述
出版日期:
2026-01-25

文章信息/Info

Title:
Regulatory RNA in Heart Failure with Preserved Ejection Fraction
作者:
段俊峰 郭美姿
(南方医科大学深圳医院全科医学科,广东 深圳 518100)
Author(s):
DUAN Junfeng; GUO Meizi
?Department of General Practice,Shenzhen Hospital of Southern Medical University,Shenzhen 518100,Guangdong,China)
关键词:
射血分数保留的心力衰竭; 调控性RNA; 非编码RNA ; 心肌重构
Keywords:
Heart failure with preserved ejection fraction; Regulatory RNA; Non-coding RNA; Myocardial remodeling
DOI:
10.16806/j.cnki.issn.1004-3934.2026.01.006
摘要:
射血分数保留的心力衰竭（HFpEF）占全部心力衰竭病例的50%以上，作为全球性的健康问题，亟需探索新的治疗策略。HFpEF的发病机制高度复杂，涉及心肌纤维化、炎症反应、代谢异常及心室重塑等多个病理过程的交互作用。近年来，调控性RNA（regRNA）逐渐成为HFpEF研究的重要方向。regRNA主要包括微小RNA（miRNA）、长链非编码RNA（lncRNA）及环状RNA（circRNA）等，regRNA通过精细调控基因表达在心血管系统中发挥关键作用，并深度参与HFpEF的发生发展过程。现综述regRNA在HFpEF中发生发展中的调控机制及其潜在的临床应用价值。值得注意的是，HFpEF患者之间regRNA表达谱存在显著异质性，这为其作为生物标志物和治疗靶点的转化应用带来挑战。未来研究进一步整合临床表型与分子分型，深入解析其作用机制，推动regRNA在HFpEF精准诊疗中的临床转化与应用。
Abstract:
Heart failure with preserved ejection fraction (HFpEF) accounts for more than 50% of all heart failure cases and represents a growing global health challenge that urgently requires the development of new therapeutic strategies. The pathogenesis of HFpEF is highly complex,involving multiple interrelated pathological processes such as myocardial fibrosis,inflammatory responses,metabolic dysregulation,and ventricular remodeling. In recent years,regulatory RNA (regRNA) has emerged as a key focus in HFpEF research. RegRNAs,primarily including microRNA (miRNA),long non-coding RNA (lncRNA),and circular RNA (circRNA),play critical role in the cardiovascular system by finely regulating gene expression and are deeply involved in the onset and progression of HFpEF. This review summarizes the regulatory mechanisms and potential clinical application value of regRNA in HFpEF. Notably,significant heterogeneity exists in the regRNA expression profiles among HFpEF patients,posing challenges to their translational use as biomarkers and therapeutic targets. Future research should focus on integrating clinical phenotypes with molecular subtypes to further elucidate the underlying mechanisms and promote the clinical translation of regRNA in the precision diagnosis and treatment of HFpEF

参考文献/References:

[1] Jalink EA,Schonk AW,Boon RA,et al. Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction[J]. Front Cardiovasc Med,2023,10:1300375.

[2] Zhang X,Yang S,Hao S,et al. Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: a pooled analysis of 12 cohort studies[J]. Eur Radiol,2024,34(3):1854-1862.

[3] Joseph J,Liu C,Hui Q,et al. Genetic architecture of heart failure with preserved versus reduced ejection fraction[J]. Nat Commun,2022,13(1):7753.

[4] He S,Zhao L,Zhang J,et al. Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction[J]. ESC Heart Fail,2024,11(5):2510-2520.

[5] Mone P,Lombardi A,Kansakar U,et al. Empagliflozin improves the microrna signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes[J]. J Pharmacol Exp Ther,2023,384(1):116-122.

[6] Gomes CPC,Schroen B,Kuster GM,et al. Regulatory RNAs in heart failure[J]. Circulation,2020,141(4):313-328.

[7] Akiyama Y,Ivanov P. tRNA-derived RNAs:biogenesis and roles in translational control[J]. Wiley Interdiscip Rev RNA,2023,14(6):e1805.

[8] Wong LL,Zou R,Zhou L,et al. Combining circulating microRNA and NT-proBNP to detect and categorize heart failure subtypes[J]. J Am Coll Cardiol,2019,73(11):1300-1313.

[9] Rinaldi S,Moroni E,Rozza R,et al. Frontiers and challenges of computing ncRNAs biogenesis,function and modulation[J]. J Chem Theory Comput,2024,20(3):993-1018.

[10] Vartak T,Kumaresan S,Brennan E. Decoding microRNA drivers in atherosclerosis[J]. Biosci Rep,2022,42(7):BSR20212355.

[11] 李汶霖，闫明静，杨尧等. 微小RNA在心力衰竭能量代谢紊乱中的作用和机制[J]. 中华心血管病杂志,2024,52(5):560-565.

[12] Glezeva N,Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target[J]. Heart Fail Rev,2014,19(5):681-694.

[13] Jensen DM,Han P,Mangala LS,et al. Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications[J]. Mol Ther,2022,30(11):3462-3476.

[14] Zhang X,McLendon JM,Peck BD,et al. Modulation of miR-29 influences myocardial compliance likely through coordinated regulation of calcium handling and extracellular matrix[J]. Mol Ther Nucleic Acids,2023,34:102081.

[15] Paim LR,da Silva LM,Antunes-Correa LM,et al. Profile of serum microRNAs in heart failure with reduced and preserved ejection fraction:correlation with myocardial remodeling[J]. Heliyon,2024,10(6):e27206.

[16] Kattih B,Fischer A,Muhly-Reinholz M,et al. Inhibition of miR-92a normalizes vascular gene expression and prevents diastolic dysfunction in heart failure with preserved ejection fraction[J]. J Mol Cell Cardiol,2025,198:89-98.

[17] Marketou M,Kontaraki J,Zacharis E,et al. Peripheral blood microRNA-21 as a predictive biomarker for heart failure with preserved ejection fraction in old hypertensives[J]. Am J Hypertens,2024,37(4):298-305.

[18] Sun H,Li X,Yuan H,et al. Comparative study of disease progression for heart failure with different etiologies via time-ordered network analysis[J]. Am J Transl Res,2022,14(9):6604-6617.

[19] Qi W,Li X,Ren Y,et al. Downregulation of lncRNA Miat contributes to the protective effect of electroacupuncture against myocardial fibrosis[J]. Chin Med,2022,17(1):57.

[20] Li B,Bai WW,Guo T,et al. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1[J]. Nat Commun,2024,15(1):2953.

[21] D’Amato A,Prosperi S,Severino P,et al. MicroRNA and heart failure: a novel promising diagnostic and therapeutic tool[J]. J Clin Med,2024,13(24):7560.

[22] Zhang Z,Zou Z,Zhang H,et al. Regulatory network analysis based on integrated miRNA-TF reveals key genes in heart failure[J]. Sci Rep,2024,14(1):13896.

[23] Cai Z,Wu C,Xu Y,et al. The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies[J]. Aging Dis,2023,14(1):46-62.

[24] Li X,Sun M,Wang Z,et al. Recent advances in mechanistic studies of heart failure with preserved ejection fraction and its comorbidities—Role of microRNAs[J]. Eur J Clin Invest,2024,54(3):e14130.

[25] Li J,Wang X. Functional roles of conserved lncRNAs and circRNAs in eukaryotes[J]. Noncoding RNA Res,2024,9(4):1271-1279.

[26] Li W,Yu J,Yang Y,et al. M3 subtype of muscarinic acetylcholine receptor inhibits cardiac fibrosis via targeting microRNA-29b/beta-site app cleaving enzyme 1 axis[J]. Cardiovasc Diagn Ther,2024,14(1):143-157.

[27] Zhao J,Huang H. Extracellular vesicle-derived non-coding RNAs: key mediators in remodelling heart failure[J]. Curr Issues Mol Biol,2024,46(9):9430-9448.

[28] Evin L,Sigutova R,Sulc P,et al. Serum levels of miR-21,miR-23a,miR-142-5p,and miR-126 in chronic failure with reduced ejection fraction: a case-control study[J]. Front Cardiovasc Med,2025,12:1529451.

[29] Zhao X,Zhong Y,Wang X,et al. Advances in circular RNA and its applications[J]. Int J Med Sci,2022,19(6):975-985.

[30] He S,Zhu H,Zhang J,et al. Genome-wide screening for circRNAs in epicardial adipose tissue of heart failure patients with preserved ejection fraction[J]. Am J Transl Res. 2023;15(7):4610-4619.

[31] Paterek A,Za??ska-Koci?cka M,Surzykiewicz M,et al. Non-coding RNA therapeutics in the treatment of heart failure[J]. Eur Heart J Cardiovasc Pharmacother,2024,10(4):353-360.

[32] Aderinto N,Abdulbasit MO,Olatunji G,et al. The promise of RNA-based therapeutics in revolutionizing heart failure management - a narrative review of current evidence[J]. Ann Med Surg(Lond),2023,85(9):4442-4453.

[33] Abbas M,Gaye A. Emerging roles of noncoding RNAs in cardiovascular pathophysiology[J]. Am J Physiol Heart Circ Physiol,2025,328(3):H603-H621.

[34] Zhang J. Non-coding RNAs and angiogenesis in cardiovascular diseases: a comprehensive review[J]. Mol Cell Biochem,2024,479(11):2921-2953.

[35] Bai H,Meng F,Ke K,et al. The significance of small noncoding RNAs in the pathogenesis of cardiovascular diseases[J]. Genes Dis,2025,12(4):101342.

[36] Sun X,Wang G,Luo W,et al. Small but strong: the emerging role of small nucleolar RNA in cardiovascular diseases[J]. Front Cell Dev Biol,2023,11:1292925.

[37] Parvan R,Rolim N,Gevaert AB,et al. Multi-microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings[J]. ESC Heart Fail,2025,12(4):3028-3041.

[38] Parvan R,Hosseinpour M,Moradi Y,et al. Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis[J]. Eur J Heart Fail,2022,24(12):2212-2225.

[39] Shen NN,Wang JL,Fu YP. The microRNA expression profiling in heart failure: a systematic review and meta-analysis[J]. Front Cardiovasc Med,2022,9:856358.

[40] Hou B,Yu D,Bai H,et al. Research progress of miRNA in heart failure: prediction and treatment[J]. J Cardiovasc Pharmacol,2024,84(2):136-145.

相似文献/References:

[1]唐欣 罗素新.心房颤动合并 射血分数保留的心力衰竭的研究进展[J].心血管病学进展,2019,(5):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
　TANG Xin,LUO Suxin.Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(1):753.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.022]
[2]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
　LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(1):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
[3]高鑫 王仲朝.射血分数保留的心力衰竭的药物治疗新进展[J].心血管病学进展,2023,(10):883.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.005]
　GAO Xin,WANG Zhongchao.New Progress in Drug Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2023,(1):883.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.005]
[4]高棣英 吴铿.SGLT2抑制剂对射血分数保留的心力衰竭的保护作用及机制研究进展[J].心血管病学进展,2024,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.008]
　GAO Diying,WU Keng.Protective Effect and Mechanism of SGLT2 Inhibitor on Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2024,(1):224.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.008]
[5]刘丰齐 王晓彦.代谢重塑在射血分数保留的心力衰竭中的研究进展[J].心血管病学进展,2024,(7):612.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.009]
　LIU Fengqi,WANG Xiaoyan.Metabolic Remodeling in Heart F ailure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2024,(1):612.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.009]
[6]王一华 蒋玉娇 门冰欣 胡娜娜 张亚苹 张锦.铁死亡在射血分数保留的心力衰竭中的研究进展[J].心血管病学进展,2024,(9):816.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.011]
　WANG Yihua,JIANG Yujiao,MEN Bingxin,et al.Ferroptosis in of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2024,(1):816.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.011]
[7]郭小雪 孙颖 王锡姝 徐冬阳 刘光辉 张志国.导管消融在射血分数保留的心力衰竭合并心房颤动治疗中的地位[J].心血管病学进展,2025,(3):205.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.004]
　GUO Xiaoxue,SUN Ying,WANG Xishu,et al.Role of Catheter Ablation in Treatment of Heart Failure with Preserved Ejection Fraction Combined with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2025,(1):205.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.004]
[8]赵珮璇 黄红琴 王丽萍 黄卿 徐敏.超声心动图评价急性心肌梗死患者左心房重构的研究进展[J].心血管病学进展,2025,(5):429.[doi:10.16806/j.cnki.issn.1004-3934.2025.05.011]
　ZHAO Peixuan,HUANG Hongqin,WANG Liping,et al.Echocardiographic Evaluation of Left Atrial Remodeling?n Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2025,(1):429.[doi:10.16806/j.cnki.issn.1004-3934.2025.05.011]
[9]姚薇 张肖 孙慧 李晋 唐彤丹.氧化应激在射血分数保留的心力衰竭中的作用与相关治疗的研究进展[J].心血管病学进展,2025,(7):609.[doi:10.16806/j.cnki.issn.1004-3934.2025.07.007]
　YAO Wei,ZHANG Xiao,SUN Hui,et al.Advances in the Role of Oxidative Stress in Heart Failure with Preserved Ejection Fraction and Related Therapy[J].Advances in Cardiovascular Diseases,2025,(1):609.[doi:10.16806/j.cnki.issn.1004-3934.2025.07.007]
[10]邓耀庭 卢伟杰 盛鹏程 刘梦洋 胡玉洁 杨康 欧小鹏 王博雯 谢萍.HFpEF合并CKD患者的联合管理策略[J].心血管病学进展,2025,(9):829.[doi:10.16806/j.cnki.issn.1004-3934.2025.09.014]
　DENG Yaoting,LU Weijie,SHENG Pengcheng,et al.Combined Management Strategies for Patients with HFpEF and CKD[J].Advances in Cardiovascular Diseases,2025,(1):829.[doi:10.16806/j.cnki.issn.1004-3934.2025.09.014]

更新日期/Last Update: 2026-05-14